Harrow (HROW) Projected to Post Quarterly Earnings on Monday

Key Points

• Harrow (HROW) will report Q1 2026 results after the close on Monday, May 11, with analysts projecting EPS of ($0.3538) and revenue of $52.43M; a conference call is scheduled for Tuesday, May 12 at 8:00 AM ET.
• Shares fell to $39.80 on Monday (50-day SMA $39.16, 200-day SMA $42.43); the company has a $1.48B market cap, a negative P/E of -234.10, and a high debt-to-equity ratio of 4.67, with a 52-week range of $21.12–$54.85.
• Wall Street sentiment is a consensus "Moderate Buy" with an average target of $69.86 (8 Buys, 2 Holds, 1 Sell), and institutional/hedge fund ownership stands at about 72.76%.

Harrow (NASDAQ:HROW - Get Free Report) is expected to be posting its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Harrow to post earnings of ($0.3538) per share and revenue of $52.4260 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.

Harrow Price Performance

Shares of NASDAQ:HROW traded down $1.10 during trading hours on Monday, hitting $39.80. 244,413 shares of the company's stock traded hands, compared to its average volume of 674,076. The company's fifty day simple moving average is $39.16 and its two-hundred day simple moving average is $42.43. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -234.10 and a beta of 0.34. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20. Harrow has a 52 week low of $21.12 and a 52 week high of $54.85.

Hedge Funds Weigh In On Harrow

Several institutional investors and hedge funds have recently added to or reduced their stakes in HROW. Royal Bank of Canada lifted its stake in Harrow by 102.5% in the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company's stock worth $261,000 after acquiring an additional 4,967 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Harrow by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company's stock valued at $483,000 after purchasing an additional 790 shares during the period. Strs Ohio purchased a new stake in shares of Harrow in the first quarter worth approximately $149,000. Legal & General Group Plc lifted its position in shares of Harrow by 12.4% in the second quarter. Legal & General Group Plc now owns 30,753 shares of the company's stock worth $939,000 after purchasing an additional 3,384 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Harrow by 9.3% during the second quarter. Rhumbline Advisers now owns 46,969 shares of the company's stock worth $1,434,000 after purchasing an additional 3,994 shares during the period. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HROW has been the subject of a number of research reports. Cantor Fitzgerald reduced their target price on shares of Harrow from $94.00 to $91.00 and set an "overweight" rating for the company in a report on Wednesday, March 4th. B. Riley Financial reiterated a "buy" rating and set a $65.00 price objective (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. Zacks Research raised Harrow from a "strong sell" rating to a "hold" rating in a research note on Friday, April 3rd. Nomura cut Harrow to a "neutral" rating in a report on Wednesday, March 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of Harrow in a research report on Thursday, March 19th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $69.86.

Harrow Company Profile

Harrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.